Sirolimus: Clinical Trials

84 trials of Sirolimus, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

41 completed, 12 recruiting, 11 terminated, 8 active not recruiting. 84 Phase 3, 26 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 384Completed 41, Recruiting 12, Terminated 11, Active not recruiting 8, Unknown 7, Not yet recruiting 3, Withdrawn 2
Phase 226Completed 9, Recruiting 7, Terminated 4, Unknown 3, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1

Follow Sirolimus: new trials by email Literature Review of Sirolimus trials Research Report on Sirolimus

Trials (filtered) newest first · largest first

All 84 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP
Sirolimus (RAPAMUNE) - Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt Phenomenon
Phase 2 / Phase 3RecruitingYi Ji762026-06-162026-06-18
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia
Phase 2 / Phase 3RecruitingChinese SLE Treatment And Research Group1642026-06-072026-06-18
A Study Comparing the MAGICTouch™ Sirolimus-coated Balloon With a Paclitaxel-coated Balloon for Treating Severe Narrowing or Blockage in the Femoropopliteal Arteries.
Sirolimus (RAPAMUNE) drug-coated balloon angioplasty catheter, Paclitaxel drug-coated balloon angioplasty - Popliteal Artery Disease, Superficial Femoral Artery Disease
Phase 2 / Phase 3Not yet recruitingConcept Medical Inc.4782026-04-012026-04-17
Systematic Approach for Children With Orbital Malformation With Sirolimus Use
Injection Sclerotherapy, Sirolimus (Rapamune®), both injection sclerotherapy and sirolimus - Orbital Lymphatic Malformation
Phase 3RecruitingAin Shams University302025-11-012026-01-30
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Cyclosporine A (CsA), Sirolimus, Ruxolitinib (JAKAVI®) - Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk
Phase 2 / Phase 3RecruitingFederal Research Institute of Pediatric Hematology, Oncology and Immunology642025-09-032026-01-26
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Sirolimus for injection (albumin bound), Octreotide long-acting injection, Everolimus - Gastroenteropancreatic Neuroendocrine Tumors
Phase 2 / Phase 3RecruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.2982025-08-292026-04-24
Combination Gerotherapeutic Interventions for Healthspan Improvement
Rapamycin, Naltrexone, Metformin - Healthspan Improvement, Aging
Phase 3CompletedAgelessRx262025-07-232026-10-30
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
INCA034176, Best Available Therapy (BAT) - Chronic Graft-versus-host-disease
Phase 3Active not recruitingIncyte Corporation92025-06-042026-08-25
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
Low-dose sirolimus, Placebo - Long COVID-19
Phase 3RecruitingIcahn School of Medicine at Mount Sinai802025-04-182026-05-18
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
Sirolimus for Injection (Albumin-bound), Fulvestrant Injection, Placebo for Sirolimus for Injection (Albumin-bound) - HR+/HER2- Advanced/Metastatic Breast Cancer
Phase 3Not yet recruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.3122025-04-012025-04-16
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
Metformin, Rapamycin, Naltrexone - Longevity, GLP-1
Phase 2 / Phase 3RecruitingAgelessRx1502024-12-172025-07-30
Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
Sirolimus (RAPAMUNE) - Lymphatic Malformation
Phase 2 / Phase 3RecruitingWest China Hospital1502024-11-302024-12-31
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
Sirolimus Topical Cream, Placebo - Solid Organ Transplant Recipients, Skin Cancer
Phase 3Active not recruitingMelanoma and Skin Cancer Trials Limited1462024-02-092025-09-09
Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza
sirolimus and oseltamivir, Oseltamivir - Influenza
Phase 3Active not recruitingChinese University of Hong Kong1602023-05-082026-10-20
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
Rapamycin, Placebo - Tuberous Sclerosis Complex
Phase 3RecruitingKatarzyna Kotulska2002023-01-232026-10-22
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
Sirolimus - Complication of Renal Dialysis, End Stage Renal Disease
Phase 3CompletedVascular Therapies, Inc.1362022-08-262026-10-06
Phase III Trial of Sirolimus in IBM
Sirolimus, Placebo - Inclusion Body Myositis
Phase 3Active not recruitingUniversity of Kansas Medical Center1402022-07-012026-01-14
Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)
Sirolimus - Juvenile Nasopharyngeal Angiofibroma
Phase 3RecruitingFederal Research Institute of Pediatric Hematology, Oncology and Immunology1172022-05-302022-09-22
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
Sirolimus - Pulmonary Fibrosis, COVID-19 Pneumonia
Phase 2 / Phase 3Active not recruitingUniversity of Chicago602021-07-092025-12-15
Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
Sirolimus - Lupus Nephritis, Immunosuppression
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital202021-06-302021-05-19

Showing 20 of 84. Sign in to see all of them.

Conditions studied

Graft vs Host Disease (7)  ·  Kidney Failure, Chronic (4)  ·  Polycystic Kidney, Autosomal Dominant (4)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)  ·  Renal Insufficiency (4)  ·  Tuberous Sclerosis (4)  ·  Bronchiolitis Obliterans Syndrome (3)  ·  Carcinoma, Hepatocellular (3)  ·  Diabetes Mellitus, Type 1 (3)  ·  Leukemia, Myeloid, Acute (3)  ·  Arteriovenous Fistula (2)  ·  Breast Neoplasms (2)  ·  Epilepsy (2)  ·  Hereditary Sensory and Autonomic Neuropathies (2)  ·  Hodgkin Disease (2)

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer (10)  ·  AgelessRx (2)  ·  CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2)  ·  Chinese SLE Treatment And Research Group (2)  ·  Cliniques universitaires Saint-Luc- Université Catholique de Louvain (2)  ·  Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2)  ·  Incyte Corporation (2)  ·  Katarzyna Kotulska (2)  ·  Medical College of Wisconsin (2)  ·  National Cancer Institute (NCI) (2)  ·  Santen Inc. (2)  ·  University of Cincinnati (2)  ·  University of Regensburg (2)  ·  Vascular Therapies, Inc. (2)  ·  Ain Shams University (1)

Countries

United States (34)  ·  France (13)  ·  Canada (12)  ·  China (10)  ·  Germany (10)  ·  Italy (9)  ·  Australia (8)  ·  United Kingdom (7)  ·  Austria (6)  ·  Netherlands (6)  ·  Spain (6)  ·  Belgium (5)  ·  Sweden (5)  ·  Czechia (4)  ·  Japan (4)

Top investigators

Andreas A Schnitzbauer, MD (2)  ·  Mary Horowitz, MD (2)  ·  Sriram Iyer, MD (2)  ·  Stefanie Morgan, PhD (2)  ·  Abha A Gupta (1)  ·  Abu Abraham, MD (1)  ·  Akinlolu Ojo, MD (1)  ·  Ali Naji, PhD (1)  ·  Andreas L. Serra, MD (1)  ·  Andrew Posselt, MD, PhD (1)  ·  Anil Kapoor, MD (1)

Results publications

PMID 19192962, PMID 39356039, PMID 15061852, PMID 15753371, PMID 16221708, PMID 17565578, PMID 17868472, PMID 19005398, PMID 19525519, PMID 19773418, PMID 20459775, PMID 20581391, PMID 20840760, PMID 21046356, PMID 21180274, PMID 21410393, PMID 22143911, PMID 22417271, PMID 22830463, PMID 22871490, PMID 23071528, PMID 23438305, PMID 23630300, PMID 23641902, PMID 23689085, PMID 24159565, PMID 24497539, PMID 24910976, PMID 24982504, PMID 25078310, PMID 25629445, PMID 25862561, PMID 25899445, PMID 25979023, PMID 26018348, PMID 26555945, PMID 26729448, PMID 26799509, PMID 26912555, PMID 27208344, PMID 27465220, PMID 27662016, PMID 28486787, PMID 28782106, PMID 29226570, PMID 29316837, PMID 29563196, PMID 29654388, PMID 29779835, PMID 29954931

NIH funding

2016 (2), U01HL069294 (2), U10CA098543 (2), U10CA180886 (2), 2005 (1), 2008 (1), P01CA018029 (1), P30CA015704 (1), U01HL131755 (1), U24CA076518 (1), U54NS065705 (1), U54RR019498 (1)